Iltamiocel is under clinical development by Cook MyoSite and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Iltamiocel’s likelihood of approval (LoA) and phase transition for Hypoactive Bladder took place on 04 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Iltamiocel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Iltamiocel overview

Cell therapy is under development for the treatment of fecal incontinence,tongue dysphagia and urological diseases such as stress urinary incontinence and underactive bladder (Hypoactive Bladder). The theraopeuticcandidate is administered through  intramuscular route. Autologous muscle-derived cell (AMDCs) possesses a high myogenic capacity and effectively regenerates both skeletal and cardiac muscle. It was also under development for advanced ischemic heart failure. It is formulated as solution for stress urinary incontinence

Quick View Iltamiocel LOA Data

Report Segments
  • Innovator
Drug Name
  • Iltamiocel
Administration Pathway
  • Intramuscular
  • Parenteral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
Key Developers
  • Sponsor Company: Cook MyoSite
  • Originator: University of Pittsburgh
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.